Flagyl ER: Effective Extended-Release Treatment for Bacterial Infections
Flagyl ER
| Product dosage: 200mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 120 | $0.37 | $44.00 (0%) | 🛒 Add to cart |
| 180 | $0.31 | $66.00 $56.00 (15%) | 🛒 Add to cart |
| 270 | $0.28 | $99.00 $75.00 (24%) | 🛒 Add to cart |
| 360 | $0.26
Best per pill | $132.00 $93.00 (30%) | 🛒 Add to cart |
Flagyl ER (metronidazole extended-release) is a prescription antimicrobial medication designed to provide sustained, effective therapy for a range of serious bacterial and parasitic infections. Its advanced extended-release formulation ensures consistent drug levels in the bloodstream, enhancing therapeutic outcomes while potentially improving patient adherence. This medication is specifically indicated for the treatment of bacterial vaginosis in adult women and is valued in clinical practice for its targeted action against anaerobic organisms and certain protozoa.
Features
- Contains 750 mg metronidazole per tablet in an extended-release formulation
- Designed for once-daily dosing to maintain stable plasma concentrations
- Film-coated tablet for ease of swallowing
- Requires prescription and medical supervision
- Manufactured under strict pharmaceutical quality standards
Benefits
- Provides sustained antimicrobial activity through extended-release technology
- Reduces dosing frequency compared to immediate-release formulations
- Effectively treats anaerobic bacterial infections and certain parasitic infestations
- Helps restore normal vaginal flora in cases of bacterial vaginosis
- Minimizes peak-trough fluctuations in drug concentration
- Supported by extensive clinical evidence of efficacy and safety
Common use
Flagyl ER is primarily prescribed for the treatment of bacterial vaginosis in non-pregnant adult women. It may also be utilized off-label for other anaerobic bacterial infections when extended-release metronidazole therapy is deemed appropriate by healthcare providers. The medication demonstrates particular effectiveness against Gram-positive and Gram-negative anaerobic bacteria, including Bacteroides species, Fusobacterium species, and Clostridium species, making it valuable in managing intra-abdominal infections, gynecological infections, and certain skin and soft tissue infections caused by susceptible anaerobic microorganisms.
Dosage and direction
The recommended dosage for bacterial vaginosis is one 750 mg extended-release tablet taken orally once daily for seven consecutive days. Tablets should be swallowed whole with a full glass of water and must not be crushed, chewed, or split. Administration with food may help minimize gastrointestinal discomfort. Treatment should be completed in full as prescribed, even if symptoms improve before finishing the course. Dosage adjustments may be necessary for patients with hepatic impairment, though no specific recommendation exists for renal impairment.
Precautions
Patients should be advised to avoid alcohol consumption during treatment and for at least 72 hours after completing therapy due to the potential for a disulfiram-like reaction characterized by nausea, vomiting, flushing, and tachycardia. Use with caution in patients with central nervous system disorders, as metronidazole has been associated with neurological adverse effects including seizures and peripheral neuropathy. Regular monitoring of blood counts is recommended during prolonged therapy due to potential hematological effects. The medication may cause dizziness or drowsiness, affecting ability to drive or operate machinery.
Contraindications
Flagyl ER is contraindicated in patients with known hypersensitivity to metronidazole, other nitroimidazole derivatives, or any component of the formulation. It should not be administered during the first trimester of pregnancy due to potential fetal risk. Contraindications also include patients who have taken disulfiram within the past two weeks and those with active organic neurologic diseases. The medication is not recommended for use in children and adolescents under 18 years of age.
Possible side effect
Common adverse reactions include nausea (approximately 12%), headache (10%), metallic taste (9%), and diarrhea (5%). Less frequently reported effects include dizziness, dry mouth, abdominal discomfort, and constipation. Serious but rare side effects may include peripheral neuropathy, seizures, encephalopathy, aseptic meningitis, and leukopenia. Allergic reactions ranging from urticaria to Stevens-Johnson syndrome have been reported. Patients should contact their healthcare provider immediately if they experience neurological symptoms, signs of infection, or severe skin reactions.
Drug interaction
Significant interactions occur with alcohol (causing disulfiram-like reaction), warfarin (potentiating anticoagulant effect), and lithium (increasing lithium toxicity risk). Concurrent use with disulfiram may precipitate psychotic episodes. Metronidazole may increase plasma concentrations of phenytoin, phenobarbital, and fluorouracil. Drugs that induce hepatic enzymes (such as phenytoin) may decrease metronidazole concentrations. Caution is advised when administering with other neurotoxic medications or CYP450 inhibitors.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next scheduled dose. In that case, the missed dose should be skipped and the regular dosing schedule resumed. Patients should not double the dose to make up for a missed one. Maintaining consistent dosing intervals is important for therapeutic efficacy, though occasional minor timing variations with extended-release formulations are generally less critical than with immediate-release products.
Overdose
Symptoms of overdose may include nausea, vomiting, ataxia, seizures, and peripheral neuropathy. There is no specific antidote for metronidazole overdose. Management involves supportive care including gastric lavage if presented early, symptomatic treatment, and monitoring of vital functions. Hemodialysis may accelerate elimination of metronidazole and its metabolites. Patients should seek immediate medical attention if overdose is suspected.
Storage
Store at controlled room temperature between 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C to 30°C (59°F to 86°F). Keep in the original container with the lid tightly closed to protect from moisture and light. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging. Properly discard any unused medication through medication take-back programs or according to FDA-recommended disposal methods.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Flagyl ER is a prescription medication that should be used only under the supervision of a qualified healthcare professional. Patients should consult their healthcare provider for diagnosis and treatment recommendations tailored to their specific medical condition. The prescribing physician should be informed of all current medications and medical history before starting treatment.
Reviews
Clinical studies demonstrate Flagyl ER’s efficacy in treating bacterial vaginosis, with complete clinical cure rates ranging from 67-82% in controlled trials. Healthcare providers report satisfaction with the extended-release formulation’s convenience and patient compliance rates. Patients appreciate the once-daily dosing regimen, though some report gastrointestinal side effects as a limitation. The medication maintains a favorable risk-benefit profile when used appropriately for indicated conditions under medical supervision.